Treace Medical Concepts, Inc. (TMCI) Stock Forecast
TMCI analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.20 / 5 from 5 analysts
- Price target
- $5.50 average of analyst targets
- Upside to target
- +42.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.25
- 52-week range
- $1.20 – $6.95
TMCI analyst ratings
5 analystsNumber of analysts at each rating.
TMCI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TMCI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.25 | −$0.25 | −$0.25 | −$0.22 | −12.8% | 1 |
| Current fiscal year (2026) | −$0.85 | −$0.88 | −$0.83 | −$0.93 | +8.5% | 5 |
| Next fiscal year (2027) | −$0.85 | −$0.85 | −$0.85 | −$0.91 | +1.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TMCI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $47.7M | $47.3M | $48.0M | −5.0% | 5 |
| Current fiscal year (2026) | $207.5M | $206.4M | $208.0M | −2.5% | 5 |
| Next fiscal year (2027) | $221.7M | $218.4M | $227.1M | +6.9% | 5 |
TMCI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TMCI revenue: reported and forecast
TMCI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.24 | −$0.24 | −$0.24 | −$0.25 | +8.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.90 | −$0.90 | −$0.85 | −$0.85 | −$0.85 | −5.5% | 5 up · 0 down |
| Next fiscal year (2027) | −$0.90 | −$0.90 | −$0.90 | −$0.90 | −$0.85 | −5.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TMCI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TMCI beat in 10 of 12.
What analysts expect from TMCI
5 analysts cover Treace Medical Concepts; their consensus rating is hold (3.20 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.50, 42.1% above the latest close of $3.87. Analysts expect earnings of −$0.85 per share for 2026, +8.5% from a year earlier. For 2027 the average estimate is −$0.85 per share on revenue of $221.7 million. Treace Medical Concepts beat the EPS estimate in 10 of the last 12 quarters.
Related: TMCI income statement, TMCI key metrics, TMCI chart. See the TMCI stock overview for the latest quote and news.
TMCI forecast FAQ
What is Treace Medical Concepts's price target?
The average analyst price target for Treace Medical Concepts is $5.50, 42.1% above the latest close of $3.87.
Is Treace Medical Concepts a buy, hold or sell?
Of 5 analysts covering Treace Medical Concepts, 1 rate it a strong buy, 0 a buy, 3 a hold, 1 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Treace Medical Concepts's EPS forecast?
Analysts forecast −$0.85 per share for 2026 (range −$0.88 to −$0.83); for 2027 the estimate is −$0.85.
What is Treace Medical Concepts's revenue forecast?
The average revenue estimate for 2026 is $207.5 million, growth of −2.5%; for 2027 it is $221.7 million.
When does Treace Medical Concepts report earnings?
Treace Medical Concepts is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.25.
Does Treace Medical Concepts usually beat earnings estimates?
Treace Medical Concepts reported EPS at or above the analyst estimate in 10 of the last 12 quarters.